151 related articles for article (PubMed ID: 33382891)
1. Plasmatic and Urinary 5-Hydroxyindolacetic Acid Measurements in Patients With Midgut Neuroendocrine Tumors: A GTE Study.
de Mestier L; Savagner F; Brixi H; Do Cao C; Dominguez-Tinajero S; Roquin G; Goichot B; Hentic O; Dubreuil O; Hautefeuille V; Walter T; Cadiot G
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1673-e1682. PubMed ID: 33382891
[TBL] [Abstract][Full Text] [Related]
2. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
3. Urinary 5-Hydroxyindolacetic Acid Measurements in Patients with Neuroendocrine Tumor-Related Carcinoid Syndrome: State of the Art.
Rossi RE; Lavezzi E; Jaafar S; Cristofolini G; Laffi A; Nappo G; Carrara S; Bertuzzi AF; Uccella S; Repici A; Zerbi A; Lania AGA
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627093
[TBL] [Abstract][Full Text] [Related]
4. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
6. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
8. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
9. Mesenteric Fibrosis in Midgut Neuroendocrine Tumors: Functionality and Radiological Features.
Rodríguez Laval V; Pavel M; Steffen IG; Baur AD; Dilz LM; Fischer C; Detjen K; Prasad V; Pascher A; Geisel D; Denecke T
Neuroendocrinology; 2018; 106(2):139-147. PubMed ID: 28384635
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
11. [Determination of thresholds values for platelet serotonin and urinary 5-HIAA concentrations for the biological diagnosis of digestive neuroendocrine tumors].
Padelli M; Bruno C; Lemarchand J; Vourc'h P; Andres C; Blasco H; Benz-de Bretagne I
Ann Biol Clin (Paris); 2019 Apr; 77(2):161-168. PubMed ID: 30998196
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
Tirosh A; Nilubol N; Patel D; Kebebew E
Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
[TBL] [Abstract][Full Text] [Related]
13. [Gastrointestinal carcinoid tumors: a multi-technique diagnostic approach].
Mathonnet M
J Chir (Paris); 2007; 144(4):287-92. PubMed ID: 17925731
[TBL] [Abstract][Full Text] [Related]
14. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
15. A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors.
Kjellman M; Knigge U; Welin S; Thiis-Evensen E; Gronbaek H; Schalin-Jäntti C; Sorbye H; Joergensen MT; Johanson V; Metso S; Waldum H; Søreide JA; Ebeling T; Lindberg F; Landerholm K; Wallin G; Salem F; Schneider MDP; Belusa R
Neuroendocrinology; 2021; 111(9):840-849. PubMed ID: 32721955
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity and Specificity of the NETest: A Validation Study.
Al-Toubah T; Cives M; Valone T; Blue K; Strosberg J
Neuroendocrinology; 2021; 111(6):580-585. PubMed ID: 32615553
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
18. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.
Dobson R; Burgess MI; Banks M; Pritchard DM; Vora J; Valle JW; Wong C; Chadwick C; George K; Keevil B; Adaway J; Ardill JE; Anthoney A; Hofmann U; Poston GJ; Cuthbertson DJ
PLoS One; 2013; 8(9):e73679. PubMed ID: 24069222
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal carcinoids: characterization by site of origin and hormone production.
Onaitis MW; Kirshbom PM; Hayward TZ; Quayle FJ; Feldman JM; Seigler HF; Tyler DS
Ann Surg; 2000 Oct; 232(4):549-56. PubMed ID: 10998653
[TBL] [Abstract][Full Text] [Related]
20. Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients.
Hilfenhaus G; Göhrig A; Pape UF; Neumann T; Jann H; Zdunek D; Hess G; Stassen JM; Wiedenmann B; Detjen K; Pavel M; Fischer C
Endocr Relat Cancer; 2013 Jun; 20(3):305-19. PubMed ID: 23463017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
